Review | Open Access | Volume 9 (4): Article  198 | Published: 22 Nov 2026

Leishmaniasis in sub-Saharan Africa: Evolving epidemiology, emerging transmission foci, and syndemic complexity

   Menu, Tables and Figures

Navigate this article

Table 1: Epidemiology of Leishmaniasis in Sub-Saharan African Countries (2010–2025)

Table 2: Recommended treatment regimens for leishmaniasis in Sub-Saharan Africa

Figure 1: Geographical Distribution of Leishmania species presentations in Sub-Saharan Africa

Figure 1: Geographical Distribution of Leishmania species presentations in Sub-Saharan Africa

Keywords

  • Leishmaniasis
  • Epidemiology
  • Coinfection
  • Diagnostics
  • Sub-Saharan Africa

Adedayo Oluwadamilola Adesida1,2, Blessing Mercy Babalola1,2, Praise Irabor2, Tobi Emmaneul Eludipo1,2, Oyetunde Timothy Oyeyemi1,2, &

1Department of Biosciences and Biotechnology, University of Medical Sciences, Ondo, Ondo State, Nigeria, 2Tropical Medicine & Diagnostics Development Group, Seeding Graduate Laboratory, University of Medical Sciences, Ondo, Ondo State, Nigeria

&Corresponding author: Oyetunde Timothy Oyeyemi, Department of Biosciences and Biotechnology, University of Medical Sciences, Ondo City, Ondo State, Nigeria, Email: ooyeyemi@unimed.edu.ng, ORCID: https://orcid.org/0000-0002-3089-2578

Received: 05 Jun 2026, Accepted: 19 Nov 2026, Published: 22 Nov 2026

Domain: Neglected Tropical Diseases

Keywords: Leishmaniasis, epidemiology, coinfection, diagnostics, sub-Saharan Africa

©Adedayo Oluwadamilola Adesida et al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Adedayo Oluwadamilola Adesida et al., Leishmaniasis in sub-Saharan Africa: Evolving epidemiology, emerging transmission foci, and syndemic complexity. Journal of Interventional Epidemiology and Public Health. 2026; 9(4):198. https://doi.org/10.37432/jieph-d-26-00176

Abstract

Leishmaniasis remains a neglected tropical disease with a complex and under-recognized epidemiology in Sub-Saharan Africa (SSA). This review synthesizes current evidence on the distribution, transmission dynamics, species diversity, coinfections, diagnostics, and control challenges of leishmaniasis across the region. Epidemiological data reveal marked heterogeneity, with cutaneous leishmaniasis (CL), predominantly caused by Leishmania major, widely distributed in West Africa, often exhibiting high focal prevalence. In contrast, visceral leishmaniasis (VL), driven mainly by Leishmania donovani, is concentrated in East Africa and the Horn of Africa, where prevalence is amplified by migration, occupational exposure, and ecological factors. Emerging evidence challenges previous assumptions of limited transmission in Southern Africa, suggesting underreporting linked to weak surveillance systems. Coinfections, particularly VL-HIV, as well as malaria, tuberculosis, and malnutrition, significantly worsen disease outcomes and complicate diagnosis and treatment. Diagnostic approaches have evolved from conventional microscopy to include serological and molecular techniques; however, access and performance remain uneven across endemic settings. Advances in molecular biology have enhanced understanding of parasite diversity, virulence, and drug resistance mechanisms, highlighting implications for treatment failure and control strategies. Therapeutic options remain limited, with increasing reliance on combination therapies, drug repurposing, and nanotechnology-based delivery systems. Overall, leishmaniasis in SSA is more widespread and operationally challenging than previously appreciated. Strengthening surveillance, improving diagnostic accessibility, addressing coinfections, and integrating molecular insights into control programs are critical to advancing effective and sustainable interventions in the region.

Introduction

Leishmaniasis is a vector-borne neglected tropical disease caused by protozoa of the genus Leishmania and transmitted by phlebotomine sandflies. Globally, the disease presents three forms, including visceral (VL), cutaneous (CL), and mucocutaneous. The VL forms can be deadly if not treated. The disease is closely linked to poverty, poor nutrition, displacement, and a weak health system, with an estimated 700,000 to 1 million new cases occurring annually across tropical and subtropical regions [1,2]. Despite sustained global attention, the epidemiology of leishmaniasis is grossly underreported, and its true burden is challenged by inadequate surveillance, limited diagnostic options and access, and frequent misclassification with other febrile or dermatological conditions.

Within this global context, the epidemiological landscape of leishmaniasis in Sub-Saharan Africa (SSA) is among the most complex. Countries in East Africa, particularly Ethiopia, Sudan, Kenya, and Uganda, remain a major focus for VL caused predominantly by Leishmania donovani. Community surveys, hospital cohorts, and migrant worker studies show prevalence ranging from 5% in general populations to over 40% in confirmed VL cohorts, alongside substantial reservoirs of asymptomatic infection that sustain transmission[3–6]. Outbreaks linked to labour migration, militia deployment, and rural occupational exposure further complicate control.

Historically, the epidemiological relevance of leishmaniasis in West Africa is considered minor; nonetheless, the region is now recognized as harbouring active CL transmission driven largely by Leishmania major. Molecular and parasitological studies in Burkina Faso, Ghana, Mali, Mauritania, Niger, Nigeria, and Senegal reveal high positivity rates among suspected cases, often exceeding 40–80%, demonstrating established endemic foci previously undocumented in regional maps of transmission [7–12].

Southern Africa has long been regarded as largely free of leishmaniasis; however, emerging reports of human CL in Angola after decades of silence and travel-associated infections linked to South Africa and Botswana suggest that this perception reflects surveillance failure rather than true absence of disease [13–15].

A critical feature of leishmaniasis epidemiology in SSA is its interaction with other endemic diseases and comorbid conditions. VL-HIV coinfection is especially prominent in Ethiopia and Sudan, where 20–40% of VL patients in some endemic zones are HIV-positive, leading to atypical clinical presentations, high relapse rates, altered drug pharmacokinetics, and elevated mortality [2,16–18]. Coinfections with malaria and tuberculosis, alongside widespread malnutrition, further complicate diagnosis, treatment outcomes, and control efforts, embedding leishmaniasis within a broader syndemic framework [19,20].

Control efforts across SSA are hindered by diagnostic limitations, weak surveillance systems, poor species identification, limited access to effective therapeutics, vector ecology knowledge gaps, and socioeconomic drivers such as migration, conflict, and poverty. Fortunately, the recent development and application of advanced molecular and diagnostic methodologies offer promising new avenues for improving disease detection and regional surveillance [21–23].

Despite sustained global attention, critical knowledge gaps continue to obscure the true burden of leishmaniasis in Sub-Saharan Africa. Specifically, transmission dynamics in non-traditional endemic zones (such as Southern Africa) remain poorly mapped due to weak surveillance; the synergistic drivers of leishmaniasis coinfections (particularly with HIV, malaria, and tuberculosis) are not fully understood within a syndemic framework; and there is a persistent disconnect between advanced molecular discoveries—such as genomic markers of drug resistance—and their practical application in field-level control programs.

To address these gaps, this review synthesizes current knowledge on the Sub-Saharan African epidemiology of leishmaniasis by integrating evidence on species distribution, transmission ecology, and emerging geographic foci. It further examines the burden imposed by syndemic coinfections and comorbidities, evaluates existing diagnostic approaches, and bridges molecular insights with public health strategies to provide a coherent evidence base for enhanced leishmaniasis control initiatives across the region.

Search strategy and selection criteria
We approached this comprehensive literature review systematically to ensure a robust and well-rounded synthesis. We identified relevant studies by searching PubMed, Scopus, and Google Scholar. Our search relied on a combination of primary keywords and Medical Subject Headings (MeSH), specifically: (“Leishmaniasis” OR “visceral leishmaniasis” OR “cutaneous leishmaniasis”) AND (“Sub-Saharan Africa” OR “West Africa” OR “East Africa” OR “Southern Africa” OR “Central Africa”)

To ensure the review reflects the most current epidemiological landscape, the search—conducted during the January–March 2026 window—was limited to articles published between January 2010 and December 2025. We included peer-reviewed research, epidemiological surveys, hospital case series, and molecular studies published in English. Studies were included if they directly addressed human Leishmania infections, transmission vectors, coinfections, or diagnostics within Sub-Saharan Africa. Studies focused entirely on non-African epidemiological settings were excluded for regional prevalence estimations, though select non-African studies were referenced comparatively for fundamental biological, structural, or methodological principles. As this was a narrative rather than a systematic review, no formal screening counts, duplicate-removal log, or pooled quantitative analysis were undertaken.

Evidence synthesis
The identified literature was synthesised narratively and organised thematically into regional epidemiology and species distribution; transmission determinants and risk patterns; coinfections and comorbidities; molecular and genetic aspects, including drug resistance; diagnostics; treatment; and control and prevention. Within each theme, studies were compared according to design, population, setting, diagnostic methods, and recency of data. Community-based surveys were used primarily to infer active transmission patterns, whereas hospital-based series were interpreted cautiously because of likely selection bias toward severe cases. Molecular and genomic studies were used to contextualise species diversity and resistance markers, while diagnostic and treatment findings were assessed against regional guidelines and field feasibility. Because study designs, case definitions, and diagnostic methods were heterogeneous, no formal meta-analysis or pooled prevalence estimates were performed; instead, emphasis was placed on consistency of findings across settings, regional representativeness, and recency. Areas of limited, conflicting, or absent evidence were explicitly identified and used to highlight remaining knowledge gaps. The synthesised evidence was then integrated into the narrative, tables, and a figure to provide a coherent basis for the conclusions and recommendations.

Epidemiology of Leishmaniasis in Sub-Saharan Africa
Leishmaniasis remains a major neglected tropical disease in Sub-Saharan Africa (SSA), manifesting predominantly as cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). Between 2010 and 2025, epidemiological investigations across Sub-Saharan Africa have revealed substantial heterogeneity in transmission intensity, affected populations, parasite species distribution, and comorbidities (Table 1 and Figure 1). Both community-based surveys and hospital-based studies demonstrate that leishmaniasis persists as a focal yet highly burdensome disease, driven by ecological, occupational, and socio-political determinants.

Cutaneous Leishmaniasis in West Africa
West Africa demonstrates sustained transmission of CL, primarily due to Leishmania major. In Burkina Faso, a retrospective hospital-based series (2012–2016) reported 44.0% parasitological positivity among suspected cases, with 96 confirmed infections in Ouagadougou [12]. This remarkably high proportion of confirmed infections among suspected cases carries profound implications for clinical practice. It suggests that healthcare providers in the region must maintain a high index of suspicion for cutaneous leishmaniasis when evaluating patients with chronic, non-healing skin ulcers, and it underscores the urgent need to integrate rapid, point-of-care diagnostic tools into primary care to ensure timely and appropriate treatment. Similarly, in Mali, retrospective parasitological analysis confirmed 41 CL cases from archived slides across multiple regions, identifying L. major as the predominant species [8]. Community-based surveys further illustrate variable endemicity within Mali, where leishmanin skin test positivity ranged from 2.7% in Kolondieba to 85.1% in Diema, with PCR confirmation of lesions in selected cases[9]. These findings highlight intense localized transmission foci.

In Ghana, cross-sectional surveys in the Oti Region identified 31.9% PCR-confirmed infection among persons with skin ulcers and 41.8% exposure by leishmanin skin testing [7], indicating substantial subclinical and active transmission. Mauritania reported a lower prevalence of 0.23% in a prospective multicenter study in Nouakchott; however, molecular typing revealed mixed circulation of L. major (61.9%) and Leishmania infantum (23.8%), underscoring species diversity [24].

Emerging data from Niger demonstrated 56.0% confirmation among suspected CL cases in Zinder, again implicating L. major [10]. In northwestern Nigeria, molecular characterization confirmed CL in 85.7% of suspected cases in Katsina State, with L. major identified as the causative agent [11]. Senegal documented 38 CL cases in a dermatology referral hospital between 2010 and 2014, reflecting continued though likely underreported transmission [25]. Collectively, CL epidemiology in West Africa is characterised by focal high-prevalence clusters, dominant transmission of L. major, and under-recognised community burden.

Visceral Leishmaniasis in East Africa and the Horn of Africa
East Africa, particularly Ethiopia, Sudan, Kenya, and Uganda, bears a disproportionate burden of VL, largely attributable to Leishmania donovani. Ethiopia remains the most extensively studied focus. Among children aged 4–15 years in Amhara Region, asymptomatic infection prevalence reached 9.9% [26]. A prospective cohort in northern Ethiopia documented 14.3% infection among volunteers in endemic areas [21]. Labour migrants in Kafta-Humera exhibited 12.5% seroprevalence, predominantly affecting males aged 15–34 years [3].

Hospital-based data reinforce high disease burden. At Metema Hospital, 21.6% of clinically suspected VL patients were confirmed positive [27]. In Oromia Region, retrospective cohort analysis (2013–2018) revealed 43.3% VL positivity among admitted patients, with substantial pediatric involvement and comorbid conditions including severe acute malnutrition, tuberculosis, malaria, and HIV [28]. Longitudinal data among HIV-infected individuals demonstrated asymptomatic VL prevalence of 12.8% in males and 4.2% in females, highlighting immunosuppression as a critical risk factor [29].

Migrant labourers constitute a particularly vulnerable population. Community-based studies in West Armachiho reported 9.6% prevalence [30]. A later prospective cohort demonstrated increasing prevalence over agricultural seasons, from 3.0% among first-time entrants at baseline to 36.4% among repeat laborers during follow-up [31], illustrating cumulative exposure risk in endemic lowland agricultural zones.

Conflict-related transmission has also emerged. In 2023, an outbreak of 1,050 CL cases among militia members in the Somali Region of eastern Ethiopia was attributed to Leishmania tropica, expanding the recognized epidemiological profile beyond traditional VL foci [32].

In Sudan, hospital-based surveillance in Gedarif identified significant coinfection rates among VL patients: 3.8% with HIV, 9.3% with malaria, and smaller proportions with hepatitis B and C [33]. These findings underscore the syndemic interaction between VL and other endemic infections.

Northern Kenya demonstrates a high VL burden. In Marsabit County, secondary data analysis revealed 80.4% positivity among confirmed VL cases evaluated between 2014 and 2017, with 83% of cases occurring in males [34]. In northeastern Uganda, community-based prevalence was 5.21%, with localized variation at the county level [6], indicating ongoing transmission outside historically recognized Ethiopian and Sudanese hotspots.
 
Leishmaniasis in Southern Africa
Leishmaniasis is relatively rare and under-documented compared to East Africa and the Horn of Africa, and the region is generally not considered a high risk for the acquisition of infection by either travelers or residents [35]. In recent years, there has been only one published report of a 15-year-old boy returning from South Africa with a cutaneous leishmaniasis ulcer and an identification of L. major [36]. The last reported cases of leishmaniasis in Namibia were over 3 decades ago [37]. There is a published report on a nurse who was diagnosed with cutaneous leishmaniasis three weeks after travelling to Botswana and visiting a game reserve. L. tropica was the implicated species in this case [13]. Although many species of Phlebotomine sandflies have been identified in Madagascar, there is no evidence to suggest that these species are capable of being vectors of Leishmania and transmitting the disease to humans. Because of this, the country is generally known to be leishmaniasis-free [14]. Although no case of human leishmaniasis had been reported in Zambia in over 4 decades, a study reporting cases of canine leishmaniasis caused by L. infantum in the country predicted the likely re-emergence of the disease [38,39]. In 2025, a pilot study using metagenomic next-generation sequencing (mNGS) on bio-banked nasopharyngeal swabs from COVID-19 patients in Lusaka, Zambia, detected molecular sequences of Leishmania (specifically matching L. braziliensis clade markers) with ~7% genomic detection rate [40]. Rather than confirmed clinical cutaneous leishmaniasis, this finding should be interpreted as molecular evidence of parasite exposure or low-level asymptomatic mucosal/respiratory colonization requiring further parasitological validation. This discovery calls for increased vigilance in monitoring leishmaniasis in the country. In addition, human cutaneous leishmaniasis has also been discovered in Angola after over 3 decades without a reported case [15].

This lack of information on the epidemiology of the disease in southern Africa is largely due to weak surveillance systems [14] and should not be interpreted as the absence of the disease. The historical perception that Southern Africa is free of leishmaniasis is likely a consequence of chronic under-detection rather than a true ecological absence of the parasite. Several intersecting factors contribute to this surveillance blind spot. First, there might be remarkably low clinical index of suspicion among healthcare providers in the region; because the disease is not traditionally considered endemic, clinicians rarely include it in their differential diagnoses. Consequently, cutaneous lesions are frequently misdiagnosed as other common tropical ulcers or bacterial skin infections, while the systemic symptoms of visceral leishmaniasis can easily be misattributed to malaria, disseminated tuberculosis, or HIV-related complications. Furthermore, the specialized diagnostic infrastructure required to confirm Leishmania infection is virtually absent in routine clinical settings across Southern Africa. Finally, because leishmaniasis is rarely integrated into national notifiable disease registries in these countries, the few cases that are accurately diagnosed often go unrecorded at the epidemiological level.

Methodological limitations and potential biases in current studies
While the data clearly show that leishmaniasis is a major burden in Sub-Saharan Africa, we have to be careful about how we interpret these numbers. The studies we currently rely on are incredibly diverse in their design, which naturally introduces a range of limitations and potential biases.

One major issue is that many regions rely heavily on hospital- or clinic-based sampling—for instance, the retrospective studies from Burkina Faso, Niger, and Senegal [10,12,25]. The problem here is selection bias: these studies only capture patients who are sick enough to need hospital care, and who have the money, transport, and access to get there. As a result, they likely overestimate the proportion of severe cases while completely missing the hidden reservoir of mild or asymptomatic infections out in the community. Conversely, community-based surveys (like those in Uganda, Ghana, and Mali) [6,7,9] give us a much better picture of local, active transmission. However, because they are often small and highly localized, we cannot easily scale their findings to estimate a true national prevalence. Additionally, studies that focus on specific high-risk groups, like migrant farm workers or military personnel in Ethiopia, give us great insight into occupational hazards, but they do not represent the everyday risk for the general public, including women and children.

Beyond who is being tested, how they are being tested makes comparing these studies exceptionally difficult. The definition of a ‘confirmed case’ varies depending on institutional diagnostic capacity, ranging from rapid diagnostic tests (RDTs) and skin tests to high-sensitivity PCR and direct microscopy. Consequently, variations in diagnostic sensitivity and specificity across tools introduce significant variance into reported prevalence rates, obscuring true epidemiological boundaries. Ultimately, this patchwork of different diagnostic tools and sampling methods means we have to exercise caution when conducting cross-country comparisons. The current literature most likely underreports the true, widespread burden of the disease across Sub-Saharan Africa, while at the same time artificially amplifying the specific hotspots where active research teams are operational.

Determinants of transmission and risk patterns
Across SSA, epidemiological patterns demonstrate consistent demographic and occupational risk gradients. Adult males engaged in farming, seasonal agricultural migration, or militia activities are disproportionately affected in VL-endemic zones [3,28,32]. Pediatric vulnerability remains evident in several Ethiopian cohorts [26,28]. HIV coinfection significantly amplifies infection risk and complicates disease dynamics [18,33].

CL transmission in West Africa appears strongly focal, often centred around rural settlements with ecological suitability for sandfly vectors. VL transmission in East Africa is associated with lowland agricultural expansion, population mobility, malnutrition, and immunosuppression. Beyond demographic and occupational risks, ecological and climatic variables serve as fundamental drivers of leishmaniasis transmission by strictly regulating both sandfly vector populations and reservoir host dynamics[41]. In Sub-Saharan Africa, seasonal rainfall and ambient temperature dictate vector abundance; warmer temperatures accelerate the development of Leishmania parasites within the sandfly gut, while specific soil moisture levels are required for breeding [42]. For instance, in East Africa, Phlebotomus vectors thrive in the unique microclimates of cracked ‘black cotton’ soils and termite mounds, which provide perfect, humid resting sites during extreme daytime heat [43].

Furthermore, anthropogenic ecological changes are rapidly shifting these traditional transmission boundaries [43]. Deforestation, unplanned urbanization, and the expansion of agricultural lands are altering local microclimates and pushing immunologically naïve human populations directly into sylvatic (wild) transmission cycles [44]. As climate change continues to drive erratic weather patterns, prolonged droughts, and shifting temperature gradients across the Sahel and the Horn of Africa, the geographic range of viable sandfly habitats is expected to expand, threatening to introduce the disease into previously unaffected or higher-altitude regions.

Coinfection and comorbidity of Leishmaniasis in Africa
Coinfection refers to the co-occurrence of leishmaniasis with other infections, such as HIV, TB, or malaria, often leading to compounded clinical manifestations, relapse rates, and death due to immunosuppression and drug pharmacokinetic changes. Malnutrition and other non-infectious comorbidities further complicate disease and treatment outcomes. The endemicity of Africa in nations such as Ethiopia, Sudan, South Sudan, and Kenya enhances these complications.

Leishmania-HIV coinfection is most common in East Africa, and Ethiopia has the highest occurrence rate, ranging from 20% to 30% [2]. Individuals with HIV are at increased risk of acquiring full-blown VL, having frequent relapses, and high mortality [2]. Antiretroviral therapy (ART) reduces these risks by slowing disease progression and improving survival [18]. In 2022, the World Health Organization published region-specific treatment guidelines for VL-HIV coinfection in East Africa. It recommended combination therapy with liposomal amphotericin B (LAmB) and miltefosine to enhance outcomes [2]. A cohort study from Ethiopia showed low exposure to antileishmanial drugs in HIV-VL patients, where the Cmax of amphotericin B was twice as low as in non-VL patients and exposure to miltefosine was 35% less in non-HIV VL cases, with a possibility of dose optimization needed for controlling elevated relapse rates [45].  ARV levels remained unaltered with antileishmanial therapy, though subtherapeutic efavirenz levels in a few patients underscore the importance of monitoring [45].  Earlier studies in 2010 indicated an increasing rate of VL-HIV coinfections in East Africa and, even more so, in Ethiopia amidst a reduction in the overall HIV cases, with clinical presentation showing atypical presentation and poorer treatment outcomes [16]. By 2016, comprehensive reviews evaluating VL-HIV co-infection across endemic areas highlighted atypical clinico-epidemiological presentations, elevated mortality risk, poor quality of life, and ongoing management challenges [46]. In highly epidemic areas like North-West Ethiopia, 19–41% of VL patients are HIV co-infected [17]. Diagnostic and treatment health care remains limited to few centers with limited clinical expertise [46].

VL-malaria coinfection presents a concern in overlapping endemic areas like West Pokot County, Kenya, where shared vectors and environmental determinants foster risks of comorbidity [20]. An observational study protocol would seek to contrast symptomatology, immunological interactions, and household determinants among mono- and coinfections and possibly inform targeted control measures [20].

In vitro studies of aminoquinoline-chalcone hybrids demonstrated dual activity against L. major and L. donovani (responsible for CL and VL, respectively), suggesting potential for treating comorbidities with malaria, though in vivo validation is needed [47]

Parasite genotype significantly influences VL mortality in Brazil, explaining up to 83% of mortality risk (heritability h² = 0.83 ± 0.17) based on L. infantum isolates from northeastern Brazil, with copy number variants (CNVs) in genes like LINF_070018000 associated with poor outcomes [48]. This genetic variation also correlates with comorbidities such as HIV and bacterial coinfections, emphasizing parasite factors in disease severity [48].

TB-VL coinfection, often in the context of HIV, represents an evidence gap, with prevalence estimates ranging from 5.7% to 29.7% in routine care settings, but diagnostic approaches are inconsistent [19]. Systematic TB screening in VL-HIV patients is advocated to assess clinical impact and enable early intervention, as TB contributes to high mortality in this group [19]. Malnutrition exacerbates progression to active disease, with diets deficient in protein, iron, vitamin A, and zinc heightening risks [2,18]. Post-kala-azar dermal leishmaniasis (PKDL), a sequel to VL comorbidity, is seen in 5-10% of the East African cases, serving as a reservoir for transmission and an earlier event in HIV-co-infected individuals [49].

Collectively, coinfections like HIV-VL and VL-malaria, comorbidities of Post-kala-azar dermal leishmaniasis (PKDL) and malnutrition, sustain a poor prognosis in Africa. Novel guidelines and pharmacokinetics demonstrate the need for tailored treatments, while diagnostic gaps in TB require heightened surveillance. Literature has documented shifting away from descriptive epidemiology to predictive modelling and region-specific interventions, reflecting novel challenges in co-endemic regions.

It is important to emphasize that the high rates and clinical severity of these coinfections do not happen in a vacuum; they are the direct result of a broader syndemic reality. The way leishmaniasis, HIV, malaria, and tuberculosis overlap and worsen one another is heavily driven by shared social, economic, and environmental factors. Issues like extreme poverty, conflict-driven displacement, severe malnutrition, and overlapping ecological vectors create the perfect storm, allowing these diseases to cluster and thrive in the most vulnerable populations.

Species distribution
Species distribution in SSA demonstrates geographic stratification. Leishmania major predominates in West African CL foci, including Burkina Faso, Mali, Niger, Nigeria, and Mauritania [8,10–12]. Leishmania donovani drives VL transmission in Ethiopia, Sudan, Kenya, and Uganda [6,26,27,34]. The emergence of Leishmania tropica in eastern Ethiopia during conflict highlights shifting epidemiological landscapes [32]. Mixed circulation, including L. infantum, has been documented in Mauritania [24]. Leishmania aethiopica is predominantly localized to the highlands of Ethiopia and Kenya, serving as a key agent of localized and diffuse cutaneous leishmaniasis [50,51].

Molecular and genetic aspects of Leishmaniasis: Strains, implications, and drug resistance gene studies
Molecular and genetic studies have vastly expanded our understanding of Leishmania strains by detailing virulence mechanisms and drug resistance. However, the true value of these molecular insights lies in their translational relevance to epidemiology and public health. For highly endemic regions in Africa, identifying the genetic markers of L. donovani (VL), L. major (CL), and L. infantum (VL/CL) is no longer just an academic exercise; it is the foundation of modern genomic surveillance. By tracking specific genetic adaptations, public health programs can map transmission networks, monitor the emergence of drug-resistant strains in real-time, and proactively adapt treatment guidelines before widespread clinical failures occur. Genome-wide screening identified 22 phosphatidylinositol-specific phospholipase C (PI-PLC) genes in L. infantum and L. major, conserved for parasite survival and immune evasion [52]. Differential expression in antimony-resistant L. infantum strains suggests PI-PLC’s role in drug susceptibility, positioning these genes as potential molecular markers for resistance monitoring [52]. Phylogenetic analysis classified PI-PLC into subfamilies, highlighting evolutionary conservation and implications for cross-strain therapies [52].

In L. donovani, dithiol glutaredoxin 1 (LdGrx1) maintains redox homeostasis and is upregulated in amphotericin B (Amp-B)-resistant strains, correlating with higher IC50 values, elevated thiols, and reduced reactive oxygen species (ROS) [53]. This cytosolic protein’s role in oxidative stress management implies it as a virulence factor enabling survival under drug pressure [53]. Whole genome sequencing (WGS) of multiple L. donovani clinical isolates from Africa and beyond has provided insights into population structure and drug resistance mechanisms, revealing genetic heterogeneity and within-host evolution [54–56]. These studies show that resistance in Brazilian Leishmania infantum isolates is linked to inherent traits observed in pretreatment isolates, specifically a deletion in the miltefosine sensitivity locus (MSL). This suggests a natural resistance mechanism present before miltefosine use in Brazil, with a significant correlation between MSL absence and higher IC50 values (P = 0.0301), predicting treatment failure with 92% sensitivity and 78% specificity [57]. Post-genomic approaches from 2013 onward have tackled resistance by expanding beyond single genes to whole-genome analyses, identifying novel markers [58]. From an epidemiological standpoint, these genomic insights are critical for field monitoring. For instance, discovering that resistance is linked to inherent traits like the miltefosine sensitivity locus (MSL) deletion means that this locus can be used as a predictive molecular marker in clinical settings [57]. Rather than waiting for a patient to fail therapy, screening for such genetic variants could allow clinicians to predict treatment failure and switch therapies early, thereby reducing mortality and preventing the further transmission of resistant strains in the community.

Refractory ML, often due to L. braziliensis (relevant for comparative insights), involves overexpression of heat shock protein 70 (HSP70) and ATPase, impairing host hydrogen peroxide production and promoting parasite persistence despite low burdens[59]. This results in treatment failures in various drugs, highlighting drug-resistant strain genetic adaptations [59]. Molecular mechanisms of drug resistance in Leishmania spp. include genomic, transcriptional, and translational control, with a review in 2024 highlighting specific mutations linked with antileishmanial drug resistance [60]

Subtractive genomics identified glutamate dehydrogenase (GDH) as a conserved Leishmania drug target with the closest phylogenetic evolutionary relationship revealed [61].  Molecular docking and simulations showed GW5074’s strong binding to GDH, suggesting it as a candidate inhibitor to combat AMR [61]. Genomic plasticity drives resistance, with reviews emphasizing the paradigm of intracellular parasite survival through gene expression changes in antimony-resistant strains [62].

Genetic engineering advances, including CRISPR/Cas and Cre-loxP systems, enable the creation of live attenuated vaccines by disrupting pathogenesis genes in L. major, offering long-term protection against virulent strains [63]. These tools overcome classical attenuation limitations, with implications for strain-specific immunity. Next-generation sequencing for drug resistance analysis in L. donovani has revealed natural population heterogeneity under treatment pressure, with implications for field monitoring [64].

Antimony-resistant L. major MON-25 maintains its phenotype post-passage through Phlebotomus papatasi, with resistance genes (e.g., LmTDR1, LmMRPA) unaltered, indicating potential field transmission despite reduced late-stage infectivity [65]. This highlights vector-parasite interactions in perpetuating resistant strains.

Ultimately, the genetic plasticity of Leishmania spp. drives not only drug resistance but also the parasite’s ability to adapt to different vectors and ecological niches across Sub-Saharan Africa. The genes driving resistance and virulence, such as PI-PLC, LdGrx1, HSP70, and GDH, should be integrated into regional epidemiological monitoring as standard biomarkers. Transitioning these molecular findings from the laboratory to the field will be essential for developing rapid point-of-care diagnostics, mapping the spread of resistant phenotypes, and designing targeted control strategies capable of outpacing the parasite’s evolution.

Diagnosis of Leishmaniasis
In Africa, laboratory confirmation of leishmaniasis has traditionally depended on a combination of clinical suspicion and parasitological verification. In endemic settings, prolonged fever, weight loss, and hepatosplenomegaly commonly raise suspicion of visceral disease, whereas chronic or ulcerative skin lesions suggest cutaneous involvement. Confirmation has historically relied on light microscopy of stained tissue aspirates or smears using Romanowsky-based stains such as Giemsa or Wright–Giemsa to visualize intracellular amastigotes [18,66]. Additional parasitological approaches include in vitro cultivation of promastigotes and experimental inoculation into animal models, typically mice, to observe disease progression. Although these methods remain accessible and relatively inexpensive, they generally permit identification only at the genus level and do not reliably differentiate species [66,67].

Diagnostic capacity in Sub-Saharan Africa has expanded with the adoption of serological assays, rapid diagnostic platforms, and molecular tools. Immunological methods detect parasite antigens or host antibodies and include latex agglutination, the Montenegro skin test, direct agglutination testing, indirect immunoblotting, hemagglutination assays, immunofluorescence antibody testing, ELISA, and immunochromatographic assays. The latex agglutination test uses antigen-coated particles and demonstrates high sensitivity, though specificity varies [68]. The Montenegro test, based on delayed-type hypersensitivity, is inexpensive and sensitive but may be negative in early visceral infection [69]. Direct agglutination testing employs trypsin-treated promastigotes and offers favorable sensitivity and specificity; however, seropositivity can persist after clinical cure [70,71]. Immunoblotting enhances diagnostic precision by detecting serum antibodies against separated parasite antigens [72]. Indirect hemagglutination assays use sensitized erythrocytes and show variable performance depending on host immune status [73]. Immunofluorescence assays are accurate but require specialized infrastructure [66]. ELISA remains widely applied because of its high diagnostic performance, although outcomes depend on antigen selection [74–76]. The rK39-based immunochromatographic test has become a principal screening tool for visceral leishmaniasis due to its speed, simplicity, and suitability for field deployment. Nonetheless, sensitivity differs geographically; reduced performance in East Africa has been linked to genetic variability among circulating strains of Leishmania donovani, limiting uniform applicability [70,71,76].

Molecular diagnostics have further strengthened detection and characterization. Polymerase chain reaction remains the most widely implemented platform, enabling amplification of parasite nucleic acids from blood, bone marrow, or tissue biopsies with superior sensitivity and species-level discrimination. It is particularly useful in relapse confirmation and epidemiological investigations. However, cost, technical requirements, and limited infrastructure restrict routine implementation in many Sub-Saharan African settings [73]. Enhanced variants have been introduced to overcome limitations of conventional PCR. Nested and semi-nested PCR improve analytical sensitivity but increase contamination risk [22,77]. Real-time PCR allows simultaneous amplification and quantification, though species discrimination may be limited in co-endemic regions [77,79]. Multiplex PCR targets multiple loci concurrently, increasing efficiency but also cost and complexity [80]. NASBA amplifies RNA targets and provides high sensitivity, yet does not reliably differentiate species [23]. For detailed genotyping and epidemiological surveillance, PCR-RFLP and AFLP enable strain-level discrimination through restriction analysis of amplified fragments, supporting detection of low parasite burdens and transmission mapping [81,82].

Loop-mediated isothermal amplification represents a promising field-adapted molecular option because it operates without thermal cycling and requires minimal equipment [83–85]. Despite technological advances, diagnostic challenges persist. The broad clinical spectrum of cutaneous disease, species diversity, and the co-endemic presence of other febrile illnesses such as tuberculosis, typhoid, and malaria contribute to delayed or missed diagnoses in many endemic regions.

While molecular diagnostics offer unparalleled sensitivity, their real-world application in Sub-Saharan Africa faces significant logistical hurdles. The routine use of PCR and targeted sequencing requires a strict cold chain for reagents, stable electricity for thermocycling, and highly trained personnel for complex DNA extractions. Because these resources are rarely available in the rural primary care clinics where the disease burden is highest, these powerful tools remain largely confined to central reference laboratories. This stark divide between diagnostic capacity and clinical need highlights the urgency for field-ready alternatives, such as freeze-dried LAMP assays, that can withstand resource-limited settings.

Advances in treatment of Leishmaniasis
Therapeutic approaches to leishmaniasis across Africa reflect regional species distribution and resource availability. In Ethiopia, localized cutaneous disease caused by Leishmania aethiopica is managed with topical paromomycin, thermotherapy, cryotherapy, and intralesional or systemic meglumine antimoniate [50]. Although intravenous pentamidine and amphotericin B formulations, including liposomal preparations, demonstrate efficacy, their use is limited [86,87]. In Kenya, intralesional antimonials are the predominant treatment modality [51]. High-dose intravenous sodium stibogluconate is effective for single lesions due to L. aethiopica, though relapses have been reported with L. tropica infections [88]. Heat therapy has also been explored but with documented recurrence. In Sudan, intravenous meglumine antimoniate and oral ketoconazole have shown clinical benefit for cutaneous and mucosal disease [88].

Across West Africa, particularly in Senegal, Mauritania, and Niger, intralesional meglumine antimoniate is commonly used against L. major [25,88]. Oral ketoconazole and metronidazole are also employed in some contexts [88]. In Ghana, cases linked to recently characterized species are frequently managed with traditional plant-based remedies or improvised thermotherapy [7]. In Cameroon, where L. major predominates, topical amphotericin B deoxycholate and oral metronidazole have been reported as effective options [88]. Data from Southern Africa remain limited, though topical paromomycin, oral fluconazole, and occasionally surgical intervention have been described, despite surgery not being generally recommended for cutaneous disease [36,88].

Rising treatment failure and emerging drug resistance have stimulated exploration of alternative strategies. Combination regimens aim to shorten treatment duration, lower toxicity, reduce relapse, and delay resistance development [89]. Field-adapted combination regimens combining short-course first- and second-line therapeutics have demonstrated substantial clinical efficacy. In Sudan, clinical evaluations of combined liposomal amphotericin B, miltefosine, and paromomycin demonstrated high cure rates and improved safety profiles in patients with post-kala-azar dermal leishmaniasis (PKDL) [90]. In immunocompromised individuals co-infected with HIV, combined miltefosine and liposomal amphotericin B has shown encouraging outcomes [90].

Drug repurposing offers an efficient strategy by evaluating approved agents for antileishmanial activity. Amphotericin B, miltefosine, azole antifungals, and sertraline have exhibited leishmanicidal effects [91,92].

Nanotechnology-based delivery systems have introduced targeted therapeutic approaches, particularly given the intracellular localization of parasites within macrophages. Liposomal and polymeric nanoparticle platforms enhance drug solubility, cellular uptake, and targeted delivery while reducing systemic toxicity [93,94]. Nanoparticle-mediated delivery has been associated with parasite killing mechanisms such as oxidative stress induction, mitochondrial membrane disruption, and inhibition of trypanothione reductase [95].

Natural products remain a significant source of candidate compounds. Extracts from Asparagus gracilis, Stellaria media, Sida cordata, and Jurinea dolomiaea have shown activity against Leishmania tropica [96–98]. Brazilian plant species, including Dipteryx alata, Hymenaea stignocarpa, and Jacaranda cuspidifolia have yielded active fractions against L. amazonensis [99,100]. Essential oils derived from medicinal plants, such as Artemisia annua, demonstrate notable leishmanicidal activity against visceral disease [101]. Alkaloids such as solamargine and solasonine from Solanum lycocarpum have surpassed standard drugs in certain models [102]. Flavonoids, lignans, coumarins, quinones, and terpenoids have also shown efficacy, including quercetin and apigenin from Kalanchoe pinnata, dehydrodieuginol, coumarins from Calophyllum brasiliense, and terpenoids such as artemisinin, (-)-α-bisabolol, ursolic acid, and oleanolic acid, with documented in vivo lesion reduction [101,103–106]. Marine-derived terpenoids from Dendrilla membranosa and Plumarella delicatissima and nanoformulated plant compounds further expand the therapeutic pipeline [107,108].

While historical and experimental therapies remain part of the literature, clinical practice in Sub-Saharan Africa is guided by specific regional protocols. Table 2 outlines the current World Health Organization (WHO) recommended therapeutic regimens, distinguishing between first-line standard of care and second-line alternatives based on the clinical presentation [2].

Challenges with control and prevention of leishmaniasis in Africa
Control and prevention of leishmaniasis in Africa remain difficult because transmission is sustained by a combination of patient, health-system, and environmental factors. Limited public awareness in endemic communities reduces early care-seeking and weakens the uptake of preventive measures, while effective control also depends on sustained community engagement and local understanding of reservoir and vector ecology [109–111].

Socioeconomic deprivation is a major barrier to prevention. Poor housing, inadequate sanitation, and unsafe waste disposal create favourable conditions for sandfly breeding and human exposure, and these risks are intensified by overcrowding and poverty. Nutritional deficiencies, including protein-energy undernutrition and shortages of iron, zinc, and vitamin A, further increase susceptibility and may worsen disease severity [1,110,112–116].

Human behaviour also contributes to transmission. Sleeping outdoors or on the ground, especially in endemic settings, increases contact with sandflies and raises infection risk. In addition, immunosuppressive conditions, particularly HIV infection, complicate diagnosis and management by increasing the risk of severe disease, relapse, and death, and by reducing the reliability of some diagnostic tests[116–118].

Health-system constraints further undermine control efforts. Leishmaniasis often mimics other febrile, dermatological, or systemic illnesses, leading to misdiagnosis and delayed treatment, especially where confirmatory laboratory capacity is limited [110,119]. Access to effective drugs is also restricted by cost, toxicity, and the need for parenteral administration, while emerging drug resistance increases the risk of treatment failure [92,110,120,121].

Environmental and structural changes add another layer of complexity. Climate change, population displacement, unplanned urbanization, conflict, and land-use change alter sandfly habitats and increase human-vector contact, creating new transmission foci [122,123]. Vector and reservoir control remains difficult because of parasite diversity, ecological heterogeneity, and the limited feasibility and sustainability of existing control measures.

Because health system capacities vary drastically across Sub-Saharan Africa, overcoming leishmaniasis requires moving away from a “one-size-fits-all” approach and adopting a context-specific, tiered strategy:

  • Tier 1 (Resource-Limited Settings): Interventions must focus on immediate morbidity reduction. Surveillance should rely on active case detection by trained community health workers. Diagnostics must be decentralized, using locally validated rapid diagnostic tests (RDTs) and microscopy. Treatment programs should prioritize a reliable supply of first-line antimonials, mandatory screening for severe malnutrition and malaria, and targeted vector control using insecticide-treated nets (ITNs) for high-risk groups like migrant workers.
  • Tier 2 (Advanced Regional Hubs): In areas with stronger infrastructure, the focus should shift to precision epidemiology. This includes using geospatial mapping to predict transmission hotspots and transitioning to field-adapted molecular tools like LAMP for species-level diagnosis[84,85]. Treatment should expand to highly effective combination therapies (e.g., liposomal amphotericin B and miltefosine)[90], supported by routine genomic surveillance to track drug resistance and proactively adapt clinical guidelines.

Ultimately, these tiered efforts must be supported by strong cross-border collaboration to effectively manage transmission among migrant and displaced populations.

Overall, effective prevention will require integrated strategies that combine community education, strengthened surveillance, improved diagnosis, affordable treatment access, and context-specific vector control.

Conclusion

Leishmaniasis in Sub-Saharan Africa is far more widespread, heterogeneous, and operationally complex than previously appreciated. Evidence from West, East, and Southern Africa shows that transmission is shaped by species diversity, ecological change, human mobility, conflict, poverty, and overlapping infections, with CL and VL posing distinct but interconnected public health challenges.

Taken together, the findings from this review underscore the need to move beyond passive recognition of the disease toward integrated, region-specific control strategies. Strengthening surveillance, expanding access to accurate species-level diagnostics, improving case management for HIV and other coinfections, and ensuring availability of safer and more effective treatments are essential to reducing missed diagnoses, relapse, and mortality.

Future progress will depend on linking molecular epidemiology with field-based public health action. Investments in vector ecology, reservoir studies, resistance monitoring, and implementation research will be critical for developing sustainable interventions and for closing the large knowledge gaps that continue to obscure the true burden of leishmaniasis across the region.

What is already known about the topic

  • Leishmaniasis remains an important neglected tropical disease in Sub-Saharan Africa;
  • Visceral leishmaniasis is concentrated in East Africa, while cutaneous leishmaniasis is common in West Africa;
  • HIV, malaria, tuberculosis, and malnutrition worsen disease outcomes and increase mortality;
  • Diagnosis and control are limited by weak surveillance, poor laboratory capacity, and emerging drug resistance.

What this  study adds

  • This review shows that leishmaniasis in Sub-Saharan Africa is more widespread than previously recognized;
  • It highlights emerging and underreported transmission foci in Southern Africa;
  • The study demonstrates clear regional differences in circulating Leishmania species;
  • It integrates recent evidence on molecular epidemiology, drug resistance, diagnostics, and new treatment strategies.

Competing interest

The authors of this work declare no competing interests.

Funding

The authors did not receive any specific funding for this work.

Authors’ contributions

Conceptualization: Oyetunde Timothy Oyeyemi
Writing – Original Draft: Oyetunde Timothy Oyeyemi, Adedayo Oluwadamilola Adesida, Blessing Mercy Babalola1, Praise Irabor, Tobi Emmaneul Eludipo
Writing – Review & Editing: Oyetunde Timothy Oyeyemi, Adedayo Oluwadamilola Adesida, Blessing Mercy Babalola1, Praise Irabor, Tobi Emmaneul Eludipo

Abbreviations
ACT: Artemisinin-based Combination Therapy
AFLP: Amplified Fragment Length Polymorphism
Amp-B: Amphotericin B
ART: Antiretroviral Therapy
ARV: Antiretroviral
CL: Cutaneous Leishmaniasis
CNV: Copy Number Variant
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats
DAT: Direct Agglutination Test
DNA: Deoxyribonucleic Acid
ELISA: Enzyme-Linked Immunosorbent Assay
GDH: Glutamate Dehydrogenase
HIV: Human Immunodeficiency Virus
HSP70: Heat Shock Protein 70
IC50: Half Maximal Inhibitory Concentration
KAtex: Latex Agglutination Test for Kala-azar
LAMP: Loop-Mediated Isothermal Amplification
LAmB: Liposomal Amphotericin B
MSL: Miltefosine Sensitivity Locus
NASBA: Nucleic Acid Sequence-Based Amplification
PCR: Polymerase Chain Reaction
PCR-RFLP: Polymerase Chain Reaction Restriction Fragment Length Polymorphism
PI-PLC: Phosphatidylinositol-Specific Phospholipase C
PKDL: Post-Kala-Azar Dermal Leishmaniasis
ROS: Reactive Oxygen Species
rK39: Recombinant Kinesin 39 Antigen
RNA: Ribonucleic Acid
SSA: Sub-Saharan Africa
TB: Tuberculosis
VL: Visceral Leishmaniasis
VL-HIV: Visceral Leishmaniasis and Human Immunodeficiency Virus Coinfection
WHO: World Health Organization
WGS: Whole Genome Sequencing

Tables & figures

Table 1: Epidemiology of Leishmaniasis in Sub-Saharan African Countries (2010–2025)

S/NoCountryPrevalenceType of StudyYear of Data CollectionPopulation TypeLocationAgeType of LeishmaniasisSpecies of LeishmaniaReference
1Burkina Faso44.0% parasitological positivity among suspected cases; 96 confirmed casesRetrospective hospital case series2012–2016Patients with suspected CLOuagadougou~30.8 years average among those with age reportedCLLeishmania major[12]
2Ghana31.9% among persons with skin ulcers detected by PCR; 41.8% exposure by leishmanin skin testCross-sectional community surveys2018Community residents and persons with skin ulcersOti Region (Ashiabre, Keri, Sibi Hilltop)Not reportedCLLeishmania spp. (PCR positive)[7]
3MaliLST positivity 85.1% (Diema), 24.6% (Kolokani), 2.7% (Kolondieba) with PCR-confirmed lesions in some casesPopulation survey using leishmanin skin test and PCR confirmation2012–2016 (community survey)General community residents in multiple districtsDistricts: Diema, Kolokani, KolondiebaMedian age: 23 yearsCLLeishmania major[9]
4Mauritania0.23%Prospective multicenter descriptive epidemiological and clinico-biological study2016–2017Patients presenting with suspected cutaneous leishmaniasis lesions at two public hospitals in NouakchottNouakchott23 yearsCLLeishmania major in 61.9% of cases; Leishmania infantum detected in 23.8% of cases[24]
5Niger56.0% (33 confirmed CL among 59 suspected)Clinic case series2023Patients with suspected CL lesionsZinder areaNot reportedCLLeishmania major[10]
6Nigeria85.7% (6/7 suspected with molecular confirmation of CL lesions)Molecular case series2024Patients with suspected CL lesionsDutsin-Ma LGA (Katsina State)Not reportedCLLeishmania major[11]
7Senegal38 cases reportedRetrospective hospital case series2010–2014Patients with CL presenting to dermatology departmentAristide Le Dantec University Hospital Dermatology, Dakar~25 yearsCLNot specified[25]
8EthiopiaDAT – 12.5%; Seroprevalence – 32.5%Cross-sectional studyOctober 2013Labour migrant workersKafta-Humera lowlands, Northwest EthiopiaRange 14–61 years (79.9% aged 15–34)VisceralLeishmania donovani[3]
9Ethiopia21.6%Cross-sectional studyJanuary 2014–June 2014Clinically suspected VL patients, predominantly males (87%), including age groups under 5 years and 15–29 years, with farmers (69.5%) and rural residents (60.9%)Metema Hospital, North Gondar Administrative Zone, Amhara region, Northwest Ethiopia28.1 years (SD 11.8, range 2–78 years)VisceralLeishmania donovani[27]
10Ethiopia9.6%Community-based cross-sectional studyOctober–December 2016Migrant laborers aged 15–65, predominantly 15–29 years (74.2%), from lowland areas (61.2%), engaged in sesame and sorghum harvestingAgricultural camps, West Armachiho district, Northwest Ethiopia15–65 yearsVisceralLeishmania donovani[30]
11Ethiopia12.8% in males and 4.2% in femalesProspective cohort2015–2016HIV-infected individualsMetema District Hospital, North-West EthiopiaMedian 38 years (IQR 30–45)VisceralLeishmania donovani[29]
12Ethiopia43.3%Retrospective cohort studySeptember 2013–September 2018VL patients, including children (51.6%), with concurrent conditions (e.g., severe acute malnutrition 27.1%, tuberculosis 6.4%, malaria 6.4%, HIV 1.1%)Negelle General Hospital, Yabello General Hospital, Ginnir General Hospital, Oromia region, EthiopiaNot reportedVisceralLeishmania donovani[28]
13Ethiopia3.0% (first comers at T1), 22.1% (repeat comers at T1), 34.8% (first comers at T2), 36.4% (repeat comers at T2)Prospective cohortJuly–August 2019 (T1) to November 2019–January 2020 (T2)Migrant workersWest Armachiho district, Northwest EthiopiaMedian 20 yearsVisceral (asymptomatic)Leishmania donovani[31]
14Uganda5.21% (95% CI: 3.15%–8.48%) in Moroto district, with county-level prevalence of 6.90% in Matheniko, 4.49% in Tepeth, and 3.61% in Moroto MunicipalityCross-sectional studyNot reported (published 2025)General community populationMoroto district, Northeastern UgandaNot reportedVisceralNot reported[6]
15EthiopiaNot reported (outbreak with 1050 cases)Cross-sectional study2023Male militia membersSomali Region, Eastern EthiopiaNot reportedCutaneousLeishmania tropica[32]
16SudanVL/HIV co-infection: 3.8%; VL/HBV co-infection: 1.9%; VL/HCV co-infection: 1.3%; VL/Malaria co-infection: 9.3%; VL/HIV/HBV/HCV/Malaria co-infection: 1.9%Retrospective, hospital-based studyJanuary 2013–June 2014Confirmed VL patients, predominantly males (75.7%), farmers (56.2%), rural residents (74.4%)Gedarif Teaching Hospital, Eastern Sudan31.4 yearsVisceralLeishmania donovani[33]
17Kenya80.4%Secondary data analysis and frequency-matched case-control study1st January 2014–11th July 2017Confirmed VL cases (83% males) and controls (age-matched, VL-negative), including children under 5 yearsMarsabit County Referral Hospital and Laisamis Mission Hospital, Northern KenyaNot reportedVisceralNot specified[34]
18Zambia~7.0%A metagenomic next-generation sequencing-based pilot study was conducted on bio-banked nasopharyngeal samplesNovember 2020–February 2021COVID-19 referral centers in Lusaka, Zambia, the University Teaching Hospital (UTH) and Levy Mwanawasa University Teaching Hospital (LMUTH)Lusaka≥18 yearsMolecular detection / Exposure (Nasopharyngeal mNGS)L. braziliensis[40]

Note: This table summarizes population-level epidemiological surveys, hospital cohorts, and community-based molecular studies. Singular clinical case reports and isolated travel-associated infections have been excluded from this summary to maintain comparability across prevalence data. CL – cutaneous leishmaniasis; VL – visceral leishmaniasis; DAT – direct agglutination test; HBV – hepatitis B virus; HCV – hepatitis C virus.

Table 2: Recommended treatment regimens for leishmaniasis in Sub-Saharan Africa

Clinical FormPrimary Regional FocusFirst-Line Recommended TreatmentSecond-Line / Alternative Treatment
Visceral Leishmaniasis (VL)East AfricaSodium Stibogluconate (SSG) + Paromomycin (PM) combinationLiposomal Amphotericin B (L-AmB) or Miltefosine
Cutaneous Leishmaniasis (CL) – UncomplicatedWest & Southern AfricaLocal therapy (Intralesional antimonials, cryotherapy, or thermotherapy)Systemic antimonials or oral Fluconazole
Cutaneous Leishmaniasis (CL) – Complex/Multiple lesionsCross-regionalSystemic antimonials (SSG or Meglumine antimoniate)Miltefosine or Liposomal Amphotericin B (L-AmB)
Figure 1: Geographical Distribution of Leishmania species presentations in Sub-Saharan Africa
Figure 1: Geographical Distribution of Leishmania species presentations in Sub-Saharan Africa
 

References

 
  1. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol [Internet]. 2006 Dec [cited 2026 Nov 22];22(12):552-7. doi:10.1016/j.pt.2006.09.004
  2. World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia [Internet]. Geneva (Switzerland): World Health Organization; 2022 Jul 7 [cited 2026 Nov 22]. 89 p. Available from: https://www.who.int/publications/i/item/9789240048294
  3. Lemma W, Tekie H, Yared S, Balkew M, Gebre-Michael T, Warburg A, Hailu A. Sero-prevalence of Leishmania donovani infection in labour migrants and entomological risk factors in extra-domestic habitats of Kafta-Humera lowlands – kala-azar endemic areas in the northwest Ethiopia. BMC Infect Dis [Internet]. 2015 Feb 26 [cited 2026 Nov 22];15:99. doi:10.1186/s12879-015-0830-2
  4. Debash H, Bisetegn H, Nigatie M, Abeje G, Feleke DG. Epidemiological, clinical and hematological profiles of visceral leishmaniasis among patients visiting Tefera Hailu Memorial Hospital, Northeast Ethiopia: a 4 year retrospective study. Sci Rep [Internet]. 2023 Jan 17 [cited 2026 Nov 22];13(1):931. doi:10.1038/s41598-023-28139-5
  5. Tesfaye S, Getu T, Yohannes T, Bekele D. Sero-prevalence of visceral leishmaniasis and associated risk factors among febrile patients attending Metema Hospital, West Gondar Zone, North West Ethiopia. Acta Parasitol [Internet]. 2024 Sep [cited 2026 Nov 22];69(3):1621-9. doi:10.1007/s11686-024-00882-3
  6. Sagaki P, Twa-Twa JM, Mulalu P, Wanume B, Olupot-Olupot P. Baseline infection prevalence, risk factors and treatment outcomes of visceral leishmaniasis in Northeastern Uganda: a cross-sectional study. PLoS Negl Trop Dis [Internet]. 2025 Jan 13 [cited 2026 Nov 22];19(1):e0012783. doi:10.1371/journal.pntd.0012783
  7. Akuffo R, Wilson M, Sarfo B, Attram N, Mosore MT, Yeboah C, Cruz I, Ruiz-Postigo JA, Boakye D, Moreno J, Anto F. Prevalence of Leishmania infection in three communities of Oti Region, Ghana. PLoS Negl Trop Dis [Internet]. 2021 May 27 [cited 2026 Nov 22];15(5):e0009413. doi:10.1371/journal.pntd.0009413
  8. Paz C, Samake S, Anderson JM, Faye O, Traore P, Tall K, Cisse M, Keita S, Valenzuela JG, Doumbia S. Leishmania major, the predominant Leishmania species responsible for cutaneous leishmaniasis in Mali. Am J Trop Med Hyg [Internet]. 2013 Mar [cited 2026 Nov 22];88(3):583-5. doi:10.4269/ajtmh.12-0434
  9. Traoré B, Oliveira F, Faye O, Dicko A, Coulibaly CA, Sissoko IM, Sibiry S, Sogoba N, Sangare MB, Coulibaly YI, Traore P, Traore SF, Anderson JM, Keita S, Valenzuela JG, Kamhawi S, Doumbia S. Prevalence of cutaneous leishmaniasis in districts of high and low endemicity in Mali. PLoS Negl Trop Dis [Internet]. 2016 Nov 29 [cited 2026 Nov 22];10(11):e0005141. doi:10.1371/journal.pntd.0005141
  10. Blaizot R, Lamine MM, Saout M, Issa K, Laminou IM, Duvignaud A, Demar M, Doutchi M. Molecular detection of Leishmania major human infections in the Zinder area, Niger. BMC Infect Dis [Internet]. 2025 Jul 1 [cited 2026 Nov 22];25(1):871. doi:10.1186/s12879-025-11229-2
  11. Enimie OE, Umar YA, Sani AM, Nkechi EL, Sherifat ABB. Molecular characterization of agents of cutaneous leishmaniasis in Dutsin-Ma Local Government Area of Katsina State, Northwestern, Nigeria. UJMR [Internet]. 2024 Jun 30 [cited 2026 Nov 22];9(3):58-64. doi:10.47430/ujmr.2493.008
  12. Sawadogo P, Guiguemdé K, Zida A, Korsaga/Somé N, Sangaré I, Bamba S, Kiemdé S, Ouédraogo/Traoré R. Retrospective study of tegumentary leishmaniasis in Burkina Faso, from 2012 to 2016. J Infectiology [Internet]. 2020 Aug 1 [cited 2026 Nov 22];3(2):4-8. doi:10.29245/2689-9981/2020/2.1159
  13. Schwartz RA, Kapila R, McElligott SC, Atkin SH, Lambert WC. Cutaneous leishmaniasis and rickettsial African tick-bite fever: a combination of exotic traveler’s diseases in the same patient. Int J Dermatol [Internet]. 2012 Aug [cited 2026 Nov 22];51(8):960-3. doi:10.1111/j.1365-4632.2011.05362.x
  14. Blavier A, Laroche L, Randrianambinintsoa FJ, Lucas V, Gantier JC, Léger N, Robert V, Depaquit J. Phlebotomine sandflies (Diptera, Psychodidae) from the Ankarana tsingy of northern Madagascar: inventory and description of new taxa. Parasite [Internet]. 2019 [cited 2026 Nov 22];26:39. doi:10.1051/parasite/2019039
  15. Cortes S, Pereira A, Vasconcelos J, Paixão JP, Quivinja J, Afonso JDM, Cristóvão JM, Campino L. PO 8505 Leishmaniasis in Angola – an emerging disease? BMJ Glob Health [Internet]. 2019 Apr [cited 2026 Nov 22];4(Suppl 3):A47.3-A48. doi:10.1136/bmjgh-2019-EDC.125
  16. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, Cuevas LE, Hailu A. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health [Internet]. 2010 Jul [cited 2026 Nov 22];15(7):848-55. doi:10.1111/j.1365-3156.2010.02550.x
  17. Welay GM, Alene KA, Dachew BA. Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia. Epidemiol Health [Internet]. 2016 Dec 28 [cited 2026 Nov 22];39:e2017001. doi:10.4178/epih.e2017001
  18. van Griensven J, Diro E. Visceral leishmaniasis: recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am [Internet]. 2019 Mar [cited 2026 Nov 22];33(1):79-99. doi:10.1016/j.idc.2018.10.005
  19. van Griensven J, Mohammed R, Ritmeijer K, Burza S, Diro E. Tuberculosis in visceral leishmaniasis-human immunodeficiency virus coinfection: an evidence gap in improving patient outcomes? Open Forum Infect Dis [Internet]. 2018 Mar 16 [cited 2026 Nov 22];5(4):ofy059. doi:10.1093/ofid/ofy059
  20. van Dijk N, Carter J, Omondi W, Mens P, Schallig H. Clinical features, immunological interactions and household determinants of visceral leishmaniasis and malaria coinfections in West Pokot, Kenya: protocol for an observational study. BMJ Open [Internet]. 2023 Apr 17 [cited 2026 Nov 22];13(4):e068679. doi:10.1136/bmjopen-2022-068679
  21. Abbasi I, Aramin S, Hailu A, Shiferaw W, Kassahun A, Belay S, Jaffe C, Warburg A. Evaluation of PCR procedures for detecting and quantifying Leishmania donovani DNA in large numbers of dried human blood samples from a visceral leishmaniasis focus in Northern Ethiopia. BMC Infect Dis [Internet]. 2013 Mar 27 [cited 2026 Nov 22];13:153. doi:10.1186/1471-2334-13-153
  22. Deepachandi B, Weerasinghe S, Soysa P, Karunaweera N, Siriwardana Y. A highly sensitive modified nested PCR to enhance case detection in leishmaniasis. BMC Infect Dis [Internet]. 2019 Jul 15 [cited 2026 Nov 22];19(1):623. doi:10.1186/s12879-019-4180-3
  23. Gow I, Smith NC, Stark D, Ellis J. Laboratory diagnostics for human Leishmania infections: a polymerase chain reaction-focussed review of detection and identification methods. Parasit Vectors [Internet]. 2022 Nov 5 [cited 2026 Nov 22];15(1):412. doi:10.1186/s13071-022-05524-z
  24. Kébé M, Ghaber SM, Aryane A, Amar ML, Yahya S, Kane A, Ely SO, Ball M. Leishmaniose cutanée: étude épidémiologique et clinico-biologique dans deux hôpitaux publics de Nouakchott [Skin leishmaniosis: epidemiological and clinical-biological study in two public hospitals in Nouakchott]. Mali Med [Internet]. 2019 [cited 2026 Nov 22];34(2):12-7. French. PMID: 35897233
  25. Diadie S, Diatta BA, Ndiaye M, Seck NB, Diallo S, Niang SO, Dieng MT. Cutaneous leishmaniasis in Senegal: a series of 38 cases at the Aristide Le Dantec University Hospital in Dakar. Med Sante Trop [Internet]. 2018 Feb 1 [cited 2026 Nov 22];28(1):106-8. doi:10.1684/mst.2017.0722
  26. Custodio E, Gadisa E, Sordo L, Cruz I, Moreno J, Nieto J, Chicharro C, Aseffa A, Abraham Z, Hailu T, Cañavate C. Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia. PLoS Negl Trop Dis [Internet]. 2012 [cited 2026 Nov 22];6(9):e1813. doi:10.1371/journal.pntd.0001813
  27. Ferede G, Diro E, Getie S, Getnet G, Takele Y, Amsalu A, Wondimeneh Y. Visceral leishmaniasis-malaria coinfection and their associated factors in patients attending Metema Hospital, Northwest Ethiopia: suggestion for integrated vector management. Malar Res Treat [Internet]. 2017 [cited 2026 Nov 22];2017:6816913. doi:10.1155/2017/6816913
  28. Tekalign S, Adera C, den Boer M, Miecha H, Zewde A, Mulugeta D, Bishawu T, Birru W, Lema A, Sahlu T, Alves F, Manzi M, Takarinda K, van Griensven J. Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia. J Infect Dev Ctries [Internet]. 2020 Jun 29 [cited 2026 Nov 22];14(6.1):42S-47S. doi:10.3855/jidc.11731
  29. van Griensven J, van Henten S, Mengesha B, Kassa M, Adem E, Endris Seid M, Abdellati S, Asefa W, Simegn T, Debasu D, Bogale T, Gedamu Y, Van den Bossche D, Adriaensen W, Van der Auwera G, Cnops L, Vogt F, Diro E. Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected individuals in North-West Ethiopia: a pilot study. PLoS Negl Trop Dis [Internet]. 2019 Oct 8 [cited 2026 Nov 22];13(10):e0007765. doi:10.1371/journal.pntd.0007765
  30. Aschale Y, Ayehu A, Worku L, Tesfa H, Birhanie M, Lemma W. Malaria-visceral leishmaniasis co-infection and associated factors among migrant laborers in West Armachiho district, North West Ethiopia: community based cross-sectional study. BMC Infect Dis [Internet]. 2019 Mar 8 [cited 2026 Nov 22];19(1):239. doi:10.1186/s12879-019-3865-y
  31. Yimer M, Takele Y, Yizengaw E, Nibret E, Sumova P, Volf P, Yismaw G, Alehegn M, Rowan A, Müller I, Cotton JA, Chapman LAC, Kropf P. Demographic characteristics and prevalence of asymptomatic Leishmania donovani infection in migrant workers working in an endemic area in Northwest Ethiopia. Front Epidemiol [Internet]. 2024 Apr 9 [cited 2026 Nov 22];4:1367387. doi:10.3389/fepid.2024.1367387
  32. Abera A, Tadesse H, Beyene D, Geleta D, Belachew M, Djirata EA, Kinde S, Difabachew H, Bishaw T, Hassen MA, Gire A, Bore TM, Berhe BM, Habtetsion M, Tugga ZO, Eyelachew E, Sefer WB, Choukri K, Coppens J, Tadese G, Haile K, Bekele H, Kebede Z, van der Auwera G, Seife F, Abte M, Tollera G, Hailu M, Dujardin JC, van Griensven J, Wolday D, Embiale W, Pareyn M, Tasew G. Outbreak of cutaneous leishmaniasis amongst militia members in a non-endemic district under conflict in the lowlands of Somali Region caused by Leishmania tropica, Eastern Ethiopia. PLoS Negl Trop Dis [Internet]. 2025 Jul 22 [cited 2026 Nov 22];19(7):e0013246. doi:10.1371/journal.pntd.0013246
  33. Hashim BM, AbdelAziem AA, Mubarak II, Khalid MG, Mona MY, Abdalazeem AI, TajEldin MA. Prevalence of hepatitis B, hepatitis C, HIV and malaria co-infection among patients infected with visceral leishmaniasis in Gedarif, Eastern Sudan. Glob J Infect Dis Clin Res [Internet]. 2016 Oct 12 [cited 2026 Nov 22];2(1):021-4. doi:10.17352/2455-5363.000010
  34. Dulacha D, Mwatha S, Lomurukai P, Owiny MO, Matini W, Irura Z, Odhiambo F, Waititu T, Matoke D, Njenga D, Boru H, Liban A, Kirigi G, Obonyo M. Epidemiological characteristics and factors associated with visceral leishmaniasis in Marsabit County, Northern Kenya. J Interv Epidemiol Public Health [Internet]. 2019 Apr 23 [cited 2026 Nov 22];2(1):3. doi:10.37432/jieph.2019.2.1.14
  35. Kwakye-Nuako G, Mosore MT, Boakye D, Bates PA. Description, biology, and medical significance of Leishmania (Mundinia) chancei n. sp. (Kinetoplastea: Trypanosomatidae) from Ghana and Leishmania (Mundinia) procaviensis n. sp. (Kinetoplastea: Trypanosomatidae) from Namibia. J Parasitol [Internet]. 2023 Jan 1 [cited 2026 Nov 22];109(1):43-50. doi:10.1645/22-53
  36. Elmehdi E, Zerkly B. Ulcère de jambe révélant la leishmaniose cutanée [Leg ulcer revealing cutaneous leishmaniasis]. Pan Afr Med J [Internet]. 2017 Aug 23 [cited 2026 Nov 22];27:287. French. doi:10.11604/pamj.2017.27.287.13090
  37. Grové SS. Leishmaniasis in South West Africa/Namibia to date. S Afr Med J [Internet]. 1989 Mar 18 [cited 2026 Nov 22];75(6):290-2. PMID: 2648612
  38. Chambaro HM, Hayashida K, Moonga LC, Shawa M, Muleya W, Chizimu J, Squarre D, Sugi T, Yamagishi J, Ogata S, Kajihara M, Sawa H, Sanjoba C, Mwase ET, Chilengi R, Munsaka GH, Sarenje KL, Mulunda NR, Mutengo MM, Namangala B, Goto Y. A high prevalence of dogs seropositive to Leishmania in Zambia. Parasitol Int [Internet]. 2025 Oct [cited 2026 Nov 22];108:103081. doi:10.1016/j.parint.2025.103081
  39. Squarre D, Chambaro HM, Hayashida K, Moonga LC, Qiu Y, Goto Y, Oparaocha E, Mumba C, Muleya W, Bwalya P, Chizimu J, Chembensofu M, Simulundu E, Mwasinga W, Banda N, Mwenda R, Yamagishi J, Nalubamba KS, Banda F, Munyeme M, Sawa H, Fandamu P. Autochthonous Leishmania infantum in dogs, Zambia, 2021. Emerg Infect Dis [Internet]. 2022 Apr [cited 2026 Nov 22];28(4):888-90. doi:10.3201/eid2804.212378
  40. Munjita SM, Tembo J, Muleya W, Bates M. Evidence of exposure to multiple zoonotic pathogens in humans in Lusaka, Zambia: insights from metagenomic next-generation sequencing. Zoonotic Dis [Internet]. 2025 May 16 [cited 2026 Nov 22];5(2):13. doi:10.3390/zoonoticdis5020013
  41. World Health Organization. Leishmaniasis [Internet]. Geneva (Switzerland): World Health Organization; 2023 Jan 12 [cited 2026 Nov 22]. [about 3 screens]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
  42. Hlavacova J, Votypka J, Volf P. The effect of temperature on Leishmania (Kinetoplastida: Trypanosomatidae) development in sand flies. J Med Entomol [Internet]. 2013 Sep [cited 2026 Nov 22];50(5):955-8. PMID: 24180098
  43. Iniguez E, Tuluso M, Kiplagat S, Gebresilassie A, Aklilu E, Battistoni O, Ingonga J, Makwatta JM, Alamin M, Dakien O, Chebet A, Kaunda E, Huffcutt P, Doh S, Cecilio P, Bonaya G, Meneses C, Serafim TD, Pareyn M, Osman M, Khalil EAG, Osman OF, Younis BM, Dorjee S, Zhou G, Valenzuela JG, Masiga DK, Musa AM, Hailu A, Satoskar A, Kamhawi S, Matoke-Muhia D. Widespread transmission in diverse ecotypes challenges visceral leishmaniasis control in East Africa. medRxiv [Preprint]. 2025 Nov 24 [cited 2026 Nov 22]:2025.10.01.25337091. doi:10.1101/2025.10.01.25337091. Update in: One Health [Internet]. 2026 Sep 20 [cited 2026 Nov 22];23:101575. doi:10.1016/j.onehlt.2026.101575
  44. Jones CM, Welburn SC. Leishmaniasis beyond East Africa. Front Vet Sci [Internet]. 2021 Feb 26 [cited 2026 Nov 22];8:618766. doi:10.3389/fvets.2021.618766
  45. Kip AE, Blesson S, Alves F, Wasunna M, Kimutai R, Menza P, Mengesha B, Beijnen JH, Hailu A, Diro E, Dorlo TPC. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study. J Antimicrob Chemother [Internet]. 2021 Apr 13 [cited 2026 Nov 22];76(5):1258-68. doi:10.1093/jac/dkab013
  46. van Griensven J, Diro E, Lopez-Velez R, Boelaert M, Lynen L, Zijlstra E, Dujardin JC, Hailu A. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis [Internet]. 2013 Mar [cited 2026 Nov 22];13(3):251-9. doi:10.1016/S1473-3099(12)70348-1
  47. Aucamp J, N’Da DD. In vitro antileishmanial efficacy of antiplasmodial active aminoquinoline-chalcone hybrids. Exp Parasitol [Internet]. 2022 May-Jun [cited 2026 Nov 22];236-237:108249. doi:10.1016/j.exppara.2022.108249
  48. Grace CA, Sousa Carvalho KS, Sousa Lima MI, Costa Silva V, Reis-Cunha JL, Brune MJ, Forrester S, Pedrozo E Silva de Azevedo CM, Costa DL, Speed D, Mottram JC, Jeffares DC, Costa CHN. Parasite genotype is a major predictor of mortality from visceral leishmaniasis. mBio [Internet]. 2022 Dec 20 [cited 2026 Nov 22];13(6):e0206822. doi:10.1128/mbio.02068-22
  49. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis [Internet]. 2003 Feb [cited 2026 Nov 22];3(2):87-98. doi:10.1016/s1473-3099(03)00517-6
  50. Tilahun Zewdu F, Tessema AM, Zerga AA, van Henten S, Lambert SM. Effectiveness of intralesional sodium stibogluconate for the treatment of localized cutaneous leishmaniasis at Boru Meda general hospital, Amhara, Ethiopia: pragmatic trial. PLoS Negl Trop Dis [Internet]. 2022 Sep 9 [cited 2026 Nov 22];16(9):e0010578. doi:10.1371/journal.pntd.0010578
  51. Grifferty G, Shirley H, O’Brien K, Hirsch JL, Orriols AM, Amechi KL, Lo J, Chanda N, El Hamzaoui S, Kahn J, Yap SV, Watson KE, Curran C, Atef AbdelAlim A, Bose N, Cilfone AL, Wamai R. The leishmaniases in Kenya: a scoping review. PLoS Negl Trop Dis [Internet]. 2023 Jun 1 [cited 2026 Nov 22];17(6):e0011358. doi:10.1371/journal.pntd.0011358
  52. Sirekbasan S, Osman SS, Gürkök-Tan T. Genomic insights into the phosphatidylinositol-specific phospholipase C gene family in Leishmania major and Leishmania infantum: expression patterns and potential association with drug resistance. Diagnostics (Basel) [Internet]. 2025 Jun 5 [cited 2026 Nov 22];15(11):1433. doi:10.3390/diagnostics15111433
  53. Priya B, Nawaz A, Rai AK, Ali V. Role of dithiol glutaredoxin 1 protein of Leishmania donovani in amphotericin B resistance and redox homeostasis. Microb Pathog [Internet]. 2025 Aug [cited 2026 Nov 22];205:107659. doi:10.1016/j.micpath.2025.107659
  54. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res [Internet]. 2011 Dec [cited 2026 Nov 22];21(12):2143-56. doi:10.1101/gr.123430.111
  55. Imamura H, Downing T, Van den Broeck F, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaerschot M, Berg M, De Muylder G, Dumetz F, Cuypers B, Maes I, Domagalska M, Decuypere S, Rai K, Uranw S, Bhattarai NR, Khanal B, Prajapati VK, Sharma S, Stark O, Schönian G, De Koning HP, Settimo L, Vanhollebeke B, Roy S, Ostyn B, Boelaert M, Maes L, Berriman M, Dujardin JC, Cotton JA. Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. Elife [Internet]. 2016 Mar 22 [cited 2026 Nov 22];5:e12613. doi:10.7554/eLife.12613
  56. Prieto Barja P, Pescher P, Bussotti G, Dumetz F, Imamura H, Kedra D, Domagalska M, Chaumeau V, Himmelbauer H, Pages M, Sterkers Y, Dujardin JC, Notredame C, Späth GF. Haplotype selection as an adaptive mechanism in the protozoan pathogen Leishmania donovani. Nat Ecol Evol [Internet]. 2017 Dec [cited 2026 Nov 22];1(12):1961-9. doi:10.1038/s41559-017-0361-x
  57. Carnielli JBT, Monti-Rocha R, Costa DL, Molina Sesana A, Pansini LNN, Segatto M, Mottram JC, Costa CHN, Carvalho SFG, Dietze R. Natural resistance of Leishmania infantum to miltefosine contributes to the low efficacy in the treatment of visceral leishmaniasis in Brazil. Am J Trop Med Hyg [Internet]. 2019 Oct [cited 2026 Nov 22];101(4):789-94. doi:10.4269/ajtmh.18-0949
  58. Berg M, Mannaert A, Vanaerschot M, Van der Auwera G, Dujardin JC. (Post-) genomic approaches to tackle drug resistance in Leishmania. Parasitology [Internet]. 2013 Oct [cited 2026 Nov 22];140(12):1492-505. doi:10.1017/S0031182013000140
  59. Urdapilleta AAA, Santos Alfani AO, Barroso DH, Vinecky F, Amaral Vaz Bandeira SDG, Andrade AC, Taquita JA, Bastos IMD, Sampaio RNR. Treatment of refractory mucosal leishmaniasis is associated with parasite overexpression of HSP70 and ATPase and reduced host hydrogen peroxide production (brief report). Biomedicines [Internet]. 2024 Sep 30 [cited 2026 Nov 22];12(10):2227. doi:10.3390/biomedicines12102227
  60. Bharadava K, Upadhyay TK, Kaushal RS, Ahmad I, Alraey Y, Siddiqui S, Saeed M. Genomic insight of Leishmania parasite: in-depth review of drug resistance mechanisms and genetic mutations. ACS Omega [Internet]. 2024 Mar 8 [cited 2026 Nov 22];9(11):12500-14. doi:10.1021/acsomega.3c09400
  61. Saha D, Jha AN. Integrated subtractive genomics and structure-based approach to unravel the therapeutic drug target of Leishmania species. Arch Microbiol [Internet]. 2024 Sep 19 [cited 2026 Nov 22];206(10):408. doi:10.1007/s00203-024-04118-w
  62. Kamran M, Bhattacharjee R, Das S, Mukherjee S, Ali N. The paradigm of intracellular parasite survival and drug resistance in leishmanial parasite through genome plasticity and epigenetics: perception and future perspective. Front Cell Infect Microbiol [Internet]. 2023 Feb 6 [cited 2026 Nov 22];13:1001973. doi:10.3389/fcimb.2023.1001973
  63. Rooholamini Z, Dianat-Moghadam H, Esmaeilifallah M, Khanahmad H. From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization. Front Public Health [Internet]. 2024 Jul 5 [cited 2026 Nov 22];12:1382996. doi:10.3389/fpubh.2024.1382996
  64. Leprohon P, Fernandez-Prada C, Gazanion É, Monte-Neto R, Ouellette M. Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist [Internet]. 2014 Sep 22 [cited 2026 Nov 22];5(1):26-35. doi:10.1016/j.ijpddr.2014.09.005
  65. Mekarnia N, Benallal KE, Sádlová J, Vojtková B, Mauras A, Imbert N, Longhitano M, Harrat Z, Volf P, Loiseau PM, Cojean S. Effect of Phlebotomus papatasi on the fitness, infectivity and antimony-resistance phenotype of antimony-resistant Leishmania major Mon-25. Int J Parasitol Drugs Drug Resist [Internet]. 2024 Aug [cited 2026 Nov 22];25:100554. doi:10.1016/j.ijpddr.2024.100554
  66. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory diagnosis of cutaneous and visceral leishmaniasis: current and future methods. Microorganisms [Internet]. 2020 Oct 22 [cited 2026 Nov 22];8(11):1632. doi:10.3390/microorganisms8111632
  67. Suárez M, Valencia BM, Jara M, Alba M, Boggild AK, Dujardin JC, Llanos-Cuentas A, Arevalo J, Adaui V. Quantification of Leishmania (Viannia) kinetoplast DNA in ulcers of cutaneous leishmaniasis reveals inter-site and inter-sampling variability in parasite load. PLoS Negl Trop Dis [Internet]. 2015 Jul 23 [cited 2026 Nov 22];9(7):e0003936. doi:10.1371/journal.pntd.0003936
  68. Salam MA, Khan MG, Mondal D. Urine antigen detection by latex agglutination test for diagnosis and assessment of initial cure of visceral leishmaniasis. Trans R Soc Trop Med Hyg [Internet]. 2011 May [cited 2026 Nov 22];105(5):269-72. doi:10.1016/j.trstmh.2010.12.007
  69. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther [Internet]. 2010 Apr [cited 2026 Nov 22];8(4):419-33. doi:10.1586/eri.10.19
  70. Bangert M, Flores-Chávez MD, Llanes-Acevedo IP, Arcones C, Chicharro C, García E, Ortega S, Nieto J, Cruz I. Validation of rK39 immunochromatographic test and direct agglutination test for the diagnosis of Mediterranean visceral leishmaniasis in Spain. PLoS Negl Trop Dis [Internet]. 2018 Mar 1 [cited 2026 Nov 22];12(3):e0006277. doi:10.1371/journal.pntd.0006277
  71. Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg [Internet]. 2008 Jan [cited 2026 Nov 22];102(1):32-40. doi:10.1016/j.trstmh.2007.09.003
  72. Heidari S, Gharechahi J, Mohebali M, Akhoundi B, Mirshahvaladi S, Azarian B, Hajjaran H. Western blot analysis of Leishmania infantum antigens in sera of patients with visceral leishmaniasis. Iran J Parasitol [Internet]. 2019 Jan-Mar [cited 2026 Nov 22];14(1):10-9. PMID: 31123464
  73. Abdoul-Latif FM, Oumaskour K, Abdallah N, Ainane A, Houmed Aboubaker I, Merito A, Mohamed H, Ainane T. Overview of research on leishmaniasis in Africa: current status, diagnosis, therapeutics, and recent advances using by-products of the Sargassaceae family. Pharmaceuticals (Basel) [Internet]. 2024 Apr 18 [cited 2026 Nov 22];17(4):523. doi:10.3390/ph17040523
  74. Carvalho FA, Charest H, Tavares CA, Matlashewski G, Valente EP, Rabello A, Gazzinelli RT, Fernandes AP. Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis [Internet]. 2002 Aug [cited 2026 Nov 22];43(4):289-95. doi:10.1016/s0732-8893(02)00410-8
  75. Dhom-Lemos L, Viana AG, Cunha JLR, Cardoso MS, Mendes TAO, Pinheiro GRG, Siqueira WF, Lobo FP, Teles LF, Bueno LL, Guimarães-Carvalho SF, Bartholomeu DC, Fujiwara RT. Leishmania infantum recombinant kinesin degenerated derived repeat (rKDDR): a novel potential antigen for serodiagnosis of visceral leishmaniasis. PLoS One [Internet]. 2019 Jan 31 [cited 2026 Nov 22];14(1):e0211719. doi:10.1371/journal.pone.0211719
  76. Maia Z, Lírio M, Mistro S, Mendes CM, Mehta SR, Badaro R. Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis [Internet]. 2012 Jan [cited 2026 Nov 22];6(1):e1484. doi:10.1371/journal.pntd.0001484
  77. da Silva MA, Pedrosa Soares CR, Medeiros RA, Medeiros Z, de Melo FL. Optimization of single-tube nested PCR for the diagnosis of visceral leishmaniasis. Exp Parasitol [Internet]. 2013 Jun [cited 2026 Nov 22];134(2):206-10. doi:10.1016/j.exppara.2013.03.003
  78. de Almeida ME, Koru O, Steurer F, Herwaldt BL, da Silva AJ. Detection and differentiation of Leishmania spp. in clinical specimens by use of a SYBR green-based real-time PCR assay. J Clin Microbiol [Internet]. 2016 Dec 28 [cited 2026 Nov 22];55(1):281-90. doi:10.1128/JCM.01764-16
  79. Weirather JL, Jeronimo SM, Gautam S, Sundar S, Kang M, Kurtz MA, Haque R, Schriefer A, Talhari S, Carvalho EM, Donelson JE, Wilson ME. Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol [Internet]. 2011 Nov [cited 2026 Nov 22];49(11):3892-904. doi:10.1128/JCM.r00764-11
  80. de Cássia-Pires R, de Melo MF, Barbosa RD, Roque AL. Multiplex PCR as a tool for the diagnosis of Leishmania spp. kDNA and the gapdh housekeeping gene of mammal hosts. PLoS One [Internet]. 2017 Mar 16 [cited 2026 Nov 22];12(3):e0173922. doi:10.1371/journal.pone.0173922
  81. Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, Sereno D. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS Negl Trop Dis [Internet]. 2016 Mar 3 [cited 2026 Nov 22];10(3):e0004349. doi:10.1371/journal.pntd.0004349. Erratum in: PLoS Negl Trop Dis [Internet]. 2016 Jun 2 [cited 2026 Nov 22];10(6):e0004770. doi:10.1371/journal.pntd.0004770
  82. Van der Auwera G, Dujardin JC. Species typing in dermal leishmaniasis. Clin Microbiol Rev [Internet]. 2015 Apr [cited 2026 Nov 22];28(2):265-94. doi:10.1128/CMR.00104-14
  83. Adams ER, Schoone G, Versteeg I, Gomez MA, Diro E, Mori Y, Perlee D, Downing T, Saravia N, Assaye A, Hailu A, Albertini A, Ndung’u JM, Schallig H. Development and evaluation of a novel loop-mediated isothermal amplification assay for diagnosis of cutaneous and visceral leishmaniasis. J Clin Microbiol [Internet]. 2018 Jun 25 [cited 2026 Nov 22];56(7):e00386-18. doi:10.1128/JCM.00386-18
  84. Khan MG, Bhaskar KR, Salam MA, Akther T, Pluschke G, Mondal D. Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients. Parasit Vectors [Internet]. 2012 Dec 3 [cited 2026 Nov 22];5:280. doi:10.1186/1756-3305-5-280
  85. Verma S, Singh R, Sharma V, Bumb RA, Negi NS, Ramesh V, Salotra P. Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of Leishmania infection. BMC Infect Dis [Internet]. 2017 Mar 23 [cited 2026 Nov 22];17(1):223. doi:10.1186/s12879-017-2318-8
  86. Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment. Trans R Soc Trop Med Hyg [Internet]. 1970 [cited 2026 Nov 22];64(3):369-79. doi:10.1016/0035-9203(70)90173-2
  87. Zanger P, Kötter I, Raible A, Gelanew T, Schönian G, Kremsner PG. Case report: successful treatment of cutaneous leishmaniasis caused by Leishmania aethiopica with liposomal amphotericin B in an immunocompromised traveler returning from Eritrea. Am J Trop Med Hyg [Internet]. 2011 May [cited 2026 Nov 22];84(5):692-4. doi:10.4269/ajtmh.2011.10-0712
  88. Blaizot R, Pasquier G, Kone AK, Duvignaud A, Demar M. Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs. Parasit Vectors [Internet]. 2024 Jul 24 [cited 2026 Nov 22];17(1):318. doi:10.1186/s13071-024-06381-8
  89. Salarkia E, Sharifi I, Keyhani A, Tavakoli Oliaee R, Khosravi A, Sharifi F, Bamorovat M, Babaei Z. In silico and in vitro potentials of crocin and amphotericin B on Leishmania major: multiple synergistic mechanisms of actions. PLoS One [Internet]. 2023 Sep 8 [cited 2026 Nov 22];18(9):e0291322. doi:10.1371/journal.pone.0291322
  90. Younis BM, Mudawi Musa A, Monnerat S, Abdelrahim Saeed M, Awad Gasim Khalil E, Elbashir Ahmed A, Ahmed Ali M, Noureldin A, Muthoni Ouattara G, Nyakaya GM, Teshome S, Omollo T, Ochieng M, Egondi T, Mmbone M, Chu WY, Dorlo TPC, Zijlstra EE, Wasunna M, Alvar J, Alves F. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: a phase II, open label, randomized, parallel arm study. PLoS Negl Trop Dis [Internet]. 2023 Nov 21 [cited 2026 Nov 22];17(11):e0011780. doi:10.1371/journal.pntd.0011780
  91. Pfarr KM, Krome AK, Al-Obaidi I, Batchelor H, Vaillant M, Hoerauf A, Opoku NO, Kuesel AC. The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use. Parasit Vectors [Internet]. 2023 Oct 31 [cited 2026 Nov 22];16(1):394. doi:10.1186/s13071-023-05909-8
  92. Paliwal A, Gahtori R, Kumari A, Pandey P. Drug resistance and repurposing of existing drugs in leishmaniasis. In: Pathogenesis, treatment and prevention of leishmaniasis [Internet]. Elsevier; 2021 [cited 2026 Nov 22]. p. 103-24. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128228005000135 doi:10.1016/B978-0-12-822800-5.00013-5
  93. Registre C, Soares RDOA, Rubio KTS, Santos ODH, Carneiro SP. A systematic review of drug-carrying nanosystems used in the treatment of leishmaniasis. ACS Infect Dis [Internet]. 2023 Mar 10 [cited 2026 Nov 22];9(3):423-49. doi:10.1021/acsinfecdis.2c00632
  94. de Carvalho Moreira LMC, de Sousa Silva ABA, de Araújo Medeiros K, Oshiro Júnior JA, da Silva DTC, de Lima Damasceno BPG. Effectiveness in vivo and in vitro of polymeric nanoparticles as a drug release system in the treatment of leishmaniasis. Curr Med Chem [Internet]. 2024 [cited 2026 Nov 22];31(3):286-307. doi:10.2174/0929867330666230120163543
  95. Abpeikar Z, Safaei M, Akbar Alizadeh A, Goodarzi A, Hatam G. The novel treatments based on tissue engineering, cell therapy and nanotechnology for cutaneous leishmaniasis. Int J Pharm [Internet]. 2023 Feb 25 [cited 2026 Nov 22];633:122615. doi:10.1016/j.ijpharm.2023.122615
  96. Iqbal K, Iqbal J, Sadaf Afreen M. Comparative study on antileishmanial and cytotoxic activity of Lawsonia inermis bark and Aloe vera leaves. IJBPAS [Internet]. 2016 [cited 2026 Nov 22];5:1490-500
  97. Koko WS, Al Nasr IS, Khan TA, Schobert R, Biersack B. An update on natural antileishmanial treatment options from plants, fungi and algae. Chem Biodivers [Internet]. 2022 Jan [cited 2026 Nov 22];19(1):e202100542. doi:10.1002/cbdv.202100542
  98. Shah NA, Khan MR, Nadhman A. Antileishmanial, toxicity, and phytochemical evaluation of medicinal plants collected from Pakistan. Biomed Res Int [Internet]. 2014 [cited 2026 Nov 22];2014:384204. doi:10.1155/2014/384204
  99. Oryan A. Plant-derived compounds in treatment of leishmaniasis. Iran J Vet Res [Internet]. 2015 Winter [cited 2026 Nov 22];16(1):1-19. PMID: 27175144
  100. Ribeiro TG, Chávez-Fumagalli MA, Valadares DG, Franca JR, Lage PS, Duarte MC, Andrade PH, Martins VT, Costa LE, Arruda AL, Faraco AA, Coelho EA, Castilho RO. Antileishmanial activity and cytotoxicity of Brazilian plants. Exp Parasitol [Internet]. 2014 Aug [cited 2026 Nov 22];143:60-8. doi:10.1016/j.exppara.2014.05.004
  101. Islamuddin M, Chouhan G, Tyagi M, Abdin MZ, Sahal D, Afrin F. Leishmanicidal activities of Artemisia annua leaf essential oil against visceral leishmaniasis. Front Microbiol [Internet]. 2014 Nov 25 [cited 2026 Nov 22];5:626. doi:10.3389/fmicb.2014.00626. Erratum in: Front Microbiol [Internet]. 2015 Sep 24 [cited 2026 Nov 22];6:1015. doi:10.3389/fmicb.2015.01015
  102. Lezama-Dávila CM, McChesney JD, Bastos JK, Miranda MA, Tiossi RF, da Costa Jde C, Bentley MV, Gaitan-Puch SE, Isaac-Márquez AP. A new antileishmanial preparation of combined solamargine and solasonine heals cutaneous leishmaniasis through different immunochemical pathways. Antimicrob Agents Chemother [Internet]. 2016 Apr 22 [cited 2026 Nov 22];60(5):2732-8. doi:10.1128/AAC.02804-15
  103. Brenzan MA, Santos AO, Nakamura CV, Filho BP, Ueda-Nakamura T, Young MC, Côrrea AG, Júnior JA, Morgado-Díaz JA, Cortez DA. Effects of (-) mammea A/BB isolated from Calophyllum brasiliense leaves and derivatives on mitochondrial membrane of Leishmania amazonensis. Phytomedicine [Internet]. 2012 Feb 15 [cited 2026 Nov 22];19(3-4):223-30. doi:10.1016/j.phymed.2011.10.008
  104. Gervazoni LFO, Barcellos GB, Ferreira-Paes T, Almeida-Amaral EE. Use of natural products in leishmaniasis chemotherapy: an overview. Front Chem [Internet]. 2020 Nov 23 [cited 2026 Nov 22];8:579891. doi:10.3389/fchem.2020.579891
  105. Muzitano MF, Falcão CA, Cruz EA, Bergonzi MC, Bilia AR, Vincieri FF, Rossi-Bergmann B, Costa SS. Oral metabolism and efficacy of Kalanchoe pinnata flavonoids in a murine model of cutaneous leishmaniasis. Planta Med [Internet]. 2009 Mar [cited 2026 Nov 22];75(4):307-11. doi:10.1055/s-0028-1088382
  106. Al-Halbosiy MMF, Ali HZ, Hassan GM, Ghaffarifar F. Artemisinin efficacy against old world Leishmania donovani: in vitro and ex vivo study. Ann Parasitol [Internet]. 2020 [cited 2026 Nov 22];66(3):295-302. doi:10.17420/ap6603.267
  107. Thomas SAL, von Salm JL, Clark S, Ferlita S, Nemani P, Azhari A, Rice CA, Wilson NG, Kyle DE, Baker BJ. Keikipukalides, furanocembrane diterpenes from the Antarctic deep sea octocoral Plumarella delicatissima. J Nat Prod [Internet]. 2018 Jan 26 [cited 2026 Nov 22];81(1):117-23. doi:10.1021/acs.jnatprod.7b00732
  108. Witowski C, Maschek A, Vesely B, Kyle D, McClintock J, Amsler C, Baker B. Characterization of membranolides B-H from Dendrilla membranosa and their activity against leishmaniasis. Planta Med [Internet]. 2014 Jul 14 [cited 2026 Nov 22];80(10):s-0034-1382374. doi:10.1055/s-0034-1382374
  109. Gouveia C, de Oliveira RM, Zwetsch A, Motta-Silva D, Carvalho BM, de Santana AF, Rangel EF. Integrated tools for American cutaneous leishmaniasis surveillance and control: intervention in an endemic area in Rio de Janeiro, RJ, Brazil. Interdiscip Perspect Infect Dis [Internet]. 2012 [cited 2026 Nov 22];2012:568312. doi:10.1155/2012/568312
  110. Bamorovat M, Sharifi I, Agha Kuchak Afshari S, Karamoozian A, Tahmouresi A, Heshmatkhah A, Salarkia E, Khosravi A, Hakimi Parizi M, Barghi M. Poor adherence is a major barrier to the proper treatment of cutaneous leishmaniasis: a case-control field assessment in Iran. Int J Parasitol Drugs Drug Resist [Internet]. 2023 Apr [cited 2026 Nov 22];21:21-7. doi:10.1016/j.ijpddr.2022.11.006
  111. Roque AL, Jansen AM. Wild and synanthropic reservoirs of Leishmania species in the Americas. Int J Parasitol Parasites Wildl [Internet]. 2014 Aug 29 [cited 2026 Nov 22];3(3):251-62. doi:10.1016/j.ijppaw.2014.08.004
  112. Bamorovat M, Sharifi I, Aflatoonian MR, Sharifi H, Karamoozian A, Sharifi F, Khosravi A, Hassanzadeh S. Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. PLoS One [Internet]. 2018 Feb 7 [cited 2026 Nov 22];13(2):e0192236. doi:10.1371/journal.pone.0192236
  113. Nweze JA, Nweze EI, Onoja US. Nutrition, malnutrition, and leishmaniasis. Nutrition [Internet]. 2020 May [cited 2026 Nov 22];73:110712. doi:10.1016/j.nut.2019.110712
  114. Reithinger R, Mohsen M, Leslie T. Risk factors for anthroponotic cutaneous leishmaniasis at the household level in Kabul, Afghanistan. PLoS Negl Trop Dis [Internet]. 2010 Mar 23 [cited 2026 Nov 22];4(3):e639. doi:10.1371/journal.pntd.0000639
  115. Monteiro MJSD, Silva MNPD, Paiva AA, Marreiro DDN, Luzia LA, Henriques GS, Rondó PHC, Sene IS, Almeida ATA, Costa CHN, Costa DL. Nutritional status and vitamin A and zinc levels in patients with kala-azar in Piauí, Brazil. Rev Soc Bras Med Trop [Internet]. 2021 Sep 6 [cited 2026 Nov 22];54:e08002020. doi:10.1590/0037-8682-0800-2020
  116. Wijerathna T, Gunathilaka N, Gunawardena K, Rodrigo W. Socioeconomic, demographic and landscape factors associated with cutaneous leishmaniasis in Kurunegala District, Sri Lanka. Parasit Vectors [Internet]. 2020 May 12 [cited 2026 Nov 22];13(1):244. doi:10.1186/s13071-020-04122-1
  117. Valero NNH, Prist P, Uriarte M. Environmental and socioeconomic risk factors for visceral and cutaneous leishmaniasis in São Paulo, Brazil. Sci Total Environ [Internet]. 2021 [cited 2026 Nov 22];797:148960. doi:10.1016/j.scitotenv.2021.148960
  118. van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect [Internet]. 2014 Apr [cited 2026 Nov 22];20(4):286-99. doi:10.1111/1469-0691.12556
  119. Firooz A, Mortazavi H, Khamesipour A, Ghiasi M, Abedini R, Balighi K, Esmaili N, Nassiri-Kashani M, Eskandari SE, Mohebali M, Mir Amin Mohammadi A, Dowlati Y. Old world cutaneous leishmaniasis in Iran: clinical variants and treatments. J Dermatolog Treat [Internet]. 2021 Nov [cited 2026 Nov 22];32(7):673-83. doi:10.1080/09546634.2019.1704214
  120. Sharifi I, Khosravi A, Aflatoonian MR, Salarkia E, Bamorovat M, Karamoozian A, Moghadam MN, Sharifi F, Afshar AA, Afshari SAK, Gharachorloo F, Shirzadi MR, Amiri B, Zainali M, Doosti S, Zamani O, Gouya MM. Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan. Front Public Health [Internet]. 2023 Apr 28 [cited 2026 Nov 22];11:1091709. doi:10.3389/fpubh.2023.1091709
  121. Yasmin H, Adhikary A, Al-Ahdal MN, Roy S, Kishore U. Host-pathogen interaction in leishmaniasis: immune response and vaccination strategies. Immuno [Internet]. 2022 Mar 9 [cited 2026 Nov 22];2(1):218-54. doi:10.3390/immuno2010015
  122. Mohammadbeigi A, Khazaei S, Heidari H, Asgarian A, Arsangjang S, Saghafipour A, Mohammadsalehi N, Ansari H. An investigation of the effects of environmental and ecologic factors on cutaneous leishmaniasis in the old world: a systematic review study. Rev Environ Health [Internet]. 2020 Sep 7 [cited 2026 Nov 22];36(1):117-28. doi:10.1515/reveh-2020-0066
  123. Karimi T, Sharifi I, Aflatoonian MR, Aflatoonian B, Mohammadi MA, Salarkia E, Babaei Z, Zarinkar F, Sharifi F, Hatami N, Khosravi A, Eskandari A, Solimani E, Shafiee M, Mozaffari M, Heshmatkhah A, Amiri R, Farajzadeh S, Kyhani A, Aghaei Afshar A, Jafarzadeh A, Bamorovat M. A long-lasting emerging epidemic of anthroponotic cutaneous leishmaniasis in southeastern Iran: population movement and peri-urban settlements as a major risk factor. Parasit Vectors [Internet]. 2021 Feb 24 [cited 2026 Nov 22];14(1):122. doi:10.1186/s13071-021-04619-3
Views: 39